Bain Capital Life Sciences
Boston, Massachusetts, United StatesFounded 2016
Bain Capital Life Sciences (BCLS) is a life sciences-focused investment firm founded in 2016 as part of Bain Capital. It invests in biopharmaceutical, medical device, diagnostic, and life science tool companies across the globe, targeting companies that drive medical innovation to improve the lives of patients with unmet medical needs.
47% of their portfolio is in Biotech & Life Sciences. Deal activity increased 75% year-over-year (7 deals in the last 12 months). Average disclosed round size is $165.5M (across 86 rounds with reported amounts).
Portfolio
65
Fund Size
$3B
Top Stage
Series B
Last 12 Mo
7
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
91 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Aiolos | Series A | $245M | Sep 2026 |
 Merida Biosciences | Series A | $121M | Aug 2026 |
 Beeline Medicines | Series A | — | Jun 2026 |
| CCereVasc, Inc. | Series C | $85M | Jun 2026 |
| Beeline Medicines | Series A | $300M | Apr 2026 |
| CCereVasc, Inc. | Series C | $85M | Jan 2026 |
| AAngitia Bio | Series D | $130M | Jan 2026 |
 Angitia Biopharmaceuticals | Series D | $130M | Jan 2026 |
| KKailera | Series B | $600M | Oct 2025 |
 Seran Bioscience | Series C | $200M | Sep 2025 |
 Apreo Health | Series B | $130M | Sep 2025 |
 Apreo Health | Series B | $130M | Sep 2025 |
 Abcuro, Inc. | Series C | $200M | Feb 2025 |
 Timberlyne Therapeutics | Series A | $180M | Jan 2025 |
| Apreo Health | Series B | $130M | Jan 2025 |
| AApreo | Unknown | $130M | Jan 2025 |
| Apreo Health | Series B | $130M | Jan 2025 |
 Kailera Therapeutics | Series A | — | Oct 2024 |
| Seran Bioscience | Growth | $200M | Sep 2024 |
 Cardurion Pharmaceuticals | Series B | $260M | Jul 2024 |
| CCereVasc, Inc. | Series B | $70M | May 2024 |
 Cidara Therapeutics | Unknown | $240M | Apr 2024 |
 Freenome | Growth | $254M | Feb 2024 |
| Seran Bioscience | Growth | $200M | Jan 2024 |
| AAiolos Bio | Series A | $245M | Oct 2023 |
Page 1 of 4
Top Co-Investors
RA Capital Management33 shared
Cormorant Asset Management16 shared
Redmile Group13 shared
Perceptive Advisors12 shared
BlackRock Private Equity Partners12 shared
OrbiMed11 shared
Logos Capital10 shared
Omega Funds10 shared
Wellington Management10 shared
Atlas Venture9 shared
Foresite Capital9 shared
T. Rowe Price8 shared
Rock Springs Capital8 shared
Longitude Capital8 shared
Adage Capital Management8 shared
Vivo Capital8 shared
HBM Healthcare Investments7 shared
Viking Global Investors7 shared
Frazier Healthcare Partners7 shared
The Invus Group, LLC7 shared
Last updated: 7 October 2026